Antifibrotic therapy for Lower Urinary Tract Symptoms secondary to Benign Prostatic Hyperplasia
4 affiliations
- 1The University of Wisconsin, School of Medicine, Madison, WI USA
- 2Loyola University, Department of Urology, Maywood, IL USA
- 3The University of Wisconsin, Department of Urology, George M. O’Brien Center, Madison, WI USA
- 4The Ohio State University Wexner Medical Center, Department of Urology, Columbus, OH USA
Abstract
Background: Lower Urinary Tract Symptoms secondary to Benign Prostatic Hyperplasia (LUTS/BPH) are a ubiquitous condition estimated to affect over 50% of men over the age of 50 years. Various treatment options exist for men presenting with LUTS/BPH, including lifestyle and behavioral modification and medical or surgical treatment. Although multiple medical treatments exist, innovation for the medical treatment of BPH has not significantly progressed.
Methods: A comprehensive narrative review was performed to evaluate prostate fibrosis as a contributor to LUTS/BPH and to identify potential antifibrotic therapies that may be applicable to the treatment of LUTS/BPH. A literature search was conducted in PubMed and ClinicalTrials.gov for molecular, translational, and clinical studies relevant to fibrosis in benign prostatic diseases. Keyword searches included “benign prostatic hyperplasia”, “lower urinary tract symptoms”, “prostate fibrosis”, “fibrosis”, “antifibrotics”, as well as combinations of these terms.
Results: In this narrative review, we review the rationale and evidence for pursuing antifibrotic therapy as a novel treatment strategy for LUTS/BPH. We discuss potential antifibrotics that could be used for the treatment of LUTS/BPH. Finally, we discuss diagnostic studies that could be used in the future to identify patients with LUTS secondary to prostate fibrosis.
Conclusions: Emerging evidence suggests that prostate fibrosis contributes to the development of LUTS. No antifibrotic therapies are currently being used, leaving LUTS secondary to fibrosis untreated. Antifibrotics are a novel medication class that could be used to treat patients who progress on current BPH medications.
Related
- Holmium laser enucleation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
- Shared mechanisms and therapeutic horizons: exploring the potential interplay between benign prostatic hyperplasia/lower urinary tract symptoms and Alzheimer’s disease
- Oxytocin Signalling in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia and Overactive Bladder Syndrome: A Narrative Review
- Non-interventional and medical management of lower urinary tract symptoms related to benign prostatic hyperplasia in men: Guidelines of the French LUTS Committee (CTMH)
- Two-dimensional computational fluid dynamics study of urine flow in the prostatic fossa after benign prostatic hyperplasia surgery: a single-patient model
BibTeX
@article{limkar2026antifibrotic,
title = {{Antifibrotic therapy for Lower Urinary Tract Symptoms secondary to Benign Prostatic Hyperplasia}},
author = {Ajinkya R. Limkar and Kevin T. McVary and William A. Ricke and Matthew S. Lee},
journal = {Prostate Cancer and Prostatic Diseases},
year = {2026},
month = may,
doi = {10.1038/s41391-026-01119-2},
url = {https://doi.org/10.1038/s41391-026-01119-2},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Antifibrotic therapy for Lower Urinary Tract Symptoms secondary to Benign Prostatic Hyperplasia
AU - Ajinkya R. Limkar
AU - Kevin T. McVary
AU - William A. Ricke
AU - Matthew S. Lee
PY - 2026
DA - 2026/05/22
JO - Prostate Cancer and Prostatic Diseases
DO - 10.1038/s41391-026-01119-2
UR - https://doi.org/10.1038/s41391-026-01119-2
AB - Background: Lower Urinary Tract Symptoms secondary to Benign Prostatic Hyperplasia (LUTS/BPH) are a ubiquitous condition estimated to affect over 50% of men over the age of 50 years. Various treatment options exist for men presenting with LUTS/BPH, including lifestyle and behavioral modification and medical or surgical treatment. Although multiple medical treatments exist, innovation for the medical treatment of BPH has not significantly progressed. Methods: A comprehensive narrative review was performed to evaluate prostate fibrosis as a contributor to LUTS/BPH and to identify potential antifibrotic therapies that may be applicable to the treatment of LUTS/BPH. A literature search was conducted in PubMed and ClinicalTrials.gov for molecular, translational, and clinical studies relevant to fibrosis in benign prostatic diseases. Keyword searches included “benign prostatic hyperplasia”, “lower urinary tract symptoms”, “prostate fibrosis”, “fibrosis”, “antifibrotics”, as well as combinations of these terms. Results: In this narrative review, we review the rationale and evidence for pursuing antifibrotic therapy as a novel treatment strategy for LUTS/BPH. We discuss potential antifibrotics that could be used for the treatment of LUTS/BPH. Finally, we discuss diagnostic studies that could be used in the future to identify patients with LUTS secondary to prostate fibrosis. Conclusions: Emerging evidence suggests that prostate fibrosis contributes to the development of LUTS. No antifibrotic therapies are currently being used, leaving LUTS secondary to fibrosis untreated. Antifibrotics are a novel medication class that could be used to treat patients who progress on current BPH medications.
SN - 1365-7852
SN - 1476-5608
ER -